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Abstract
Background: Research related to cancer is vast, and continues in earnest in many directions. Due to the
complexity of cancer, a better understanding of tumor growth dynamics can be gleaned from a dynamic
computational model. We present a comprehensive, fully executable, spatial and temporal 3D computational model
of the development of a cancerous tumor together with its environment.
Results: The model was created using Statecharts, which were then connected to an interactive animation front-end
that we developed especially for this work, making it possible to visualize on the fly the on-going events of the
system’s execution, as well as the effect of various input parameters. We were thus able to gain a better understanding
of, e.g., how different amounts or thresholds of oxygen and VEGF (vascular endothelial growth factor) affect the
progression of the tumor. We found that the tumor has a critical turning point, where it either dies or recovers. If
minimum conditions are met at that time, it eventually develops into a full, active, growing tumor, regardless of the
actual amount; otherwise it dies.
Conclusions: This brings us to the conclusion that the tumor is in fact a very robust system: changing initial values of
VEGF and oxygen can increase the time it takes to become fully developed, but will not necessarily completely
eliminate it.
Keywords: Computational models, Biological systems, Statecharts, Tumor and its microenvironment, Visualization
Abbreviations: CAF, Cancer associated fibroblast; ECM, Extra cellular matrix; FGF, Fibroblast growth factor;
HGF, Hepatocyte growth factor; RA, Reactive animation; VEGF, Vascular endothelial growth factor
Background
Cancer, a state of abnormal growth and regulation of
cells, which proliferate in an uncontrolled way, is among
the leading causes of mortality worldwide. Researching
cancer is of high importance.
The dynamic microenvironment in which a tumor
originates, also termed the stroma, plays a critical role in
tumor initiation and progression, and may be an import-
ant factor in developing therapeutic approaches. For
years, research has focused on understanding the trans-
formation of normal cells into neoplastic or cancerous
ones. However, it has become evident that the surround-
ing environment of the tumor cells is equally important.
Cells that surround the tumor and can take part in its
development include innate and adaptive immune cells,
fibroblasts [1], cells that line the blood and lymphatic
vessels, and the proteins that make up the structural
component–the extra cellular matrix (ECM). The tumor
cannot survive or progress on its own [2, 3]; it entirely
depends on this dynamic microenvironment in which it
originates and the bi-directional interactions with this
surroundings [4, 5]. These include secretion of signals or
cell-cell interactions and can act to either enhance or
block tumor formation. The conditions within the
tumor’s microenvironment differ considerably from
those in normal tissue.
Angiogenesis, the process of new blood vessels growing
from pre-existing ones, is an essential step in the transi-
tion of tumors from a dormant state to a malignant one.
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The new blood vessels grow towards the tumor and feed
it with large supplies of oxygen and nutrients. Without
angiogenesis, tumors cannot grow beyond the size of
1 mm3. The process leading to angiogenesis begins when
the tumor cells lack oxygen (a state of hypoxia), and is
followed by a series of events, orchestrated by a variety of
activators and inhibitors.
There is a balance between the pro- and anti-
angiogenic factors and when this balance tips in favor of
the pro-angiogenesis, the onset of angiogenesis, or the
angiogenic switch, is induced [6]. The tumor cells
release (or cause nearby cells to produce) angiogenic fac-
tors that stimulate the formation of blood vessels and
recruit them to the tumor’s area [7].
A major activator of the proliferation and migration of
the endothelial-cell (the vessels lining) is the vascular
endothelial growth factor (VEGF). The endothelial cell at
the tip of the emerging vessel starts to migrate towards
the angiogenic signals by sensing the concentration
gradient [8, 9], while in the stem of the newly formed
vessel the endothelial cells proliferate, adhere to each
other and create a lumen (the inner space of the tubular
vessel). Indeed, blocking angiogenesis by inserting anti-
angiogenic factors has been a strategy for clinicians in
their efforts to arrest tumor growth [10].
Computational approaches have become a big part of
biological research. Computational modeling of bio-
logical systems provides a means to integrate a large
amount of data and generate a comprehensive overview
of the behavior of a system as a whole [11, 12]. Further-
more, being able to visualize animations of the model in
operation can significantly aid in gaining a clear under-
standing of complex biological behavior, and together
can serve as a beneficial way to analyze the system and
make new discoveries.
Due to the complexity of cancer, a better understanding
of tumor growth dynamics and insights into the cancer’s
behavior can be gleaned from a dynamic computational
visual model. We have therefore focused on modeling the
cancerous tumor and its microenvironment and bringing
it to life with an interactive animation tool.
Cancer, given its clinical importance, has been studied
in detail, and is continuously under intensive investiga-
tion. A multitude of experimental, clinical and theoret-
ical studies exist and have shed light on many aspects of
cancer on all levels: the sub-cellular scale (e.g., DNA and
proteins) [13, 14], cellular scale (activation, proliferation,
interactions) [15, 16], and system scale (cell migration,
diffusion, metastasis) [17, 18]. Given its complexity and
multiscale nature, a better understanding of tumor
growth dynamics can be expected from a suitable
approach to computational modeling [19–21].
Extensive attempts have been carried out to model
and analyze cancer, or particular facets thereof [22, 23];
for the most part, this is done by traditional mathemat-
ical modeling [24–30], using a top-down approach,
whereby the behavior of the system is inserted into the
model. [31–41]. Modeling work on cancer using agent
based methods has also been used ([42, 43]).
Our goal was to create a comprehensive model of the
entire system, whereby we first model and only then ask
the questions and not the other way around. This ap-
proach, sometimes termed ‘executable biology’ [44–49],
focuses on designing executable models that mimic
complex biological phenomena. It is carried out in a
bottom-up fashion, whereby the behavior of each of the
elements of the system (e.g., cells) is described individu-
ally, and the system’s overall behavior emerges from
those of its many elements. The main language used to
build our model is the visual formalism of Statecharts.
We connected our Statechart model to SimuLife, an
animation tool that we built especially in our group for
viewing the behaviors of such biological models, and
which thus serves as a sort of front end to them [50].
SimuLife, based on the technique of reactive animation
(RA) [51, 52], is 3D, web-based, and easy to use via an
intuitive interface. Visualization of the cancer model is im-
portant, as it enables one to see the development and
morphology of the tumor and its surroundings based on
its individual components. It can be used to fine-tune the
model, visualize the effect of changing elements or param-
eter values, and to verify the behavior of the system.
Results and discussion
We created a comprehensive, fully executable, spatial
and temporal 3D computational model that demon-
strates the behavior of a typical cancerous solid tumor
together with its microenvironment, treating it some-
what like a developing organ.
The model captures the ongoing bidirectional cross talk
between the tumor and its surroundings, which plays a
critical role in tumor initiation and progression, so that
researching the dynamic behavior and morphology of this
system via such a model should be of great interest.
The way we chose to build the model is in a bottom-
up fashion, whereby the behavior of each of the system’s
elements is described individually, using only the
fundamental building blocks of that element. The
system’s overall behavior emerges from that of the ele-
ments thereof, which is the essence of realistic modeling.
The tumor model in Statecharts
Using Statecharts, a generic program of behavior was
created for each of the different types of the objects.
During an execution of the model many instances of the
objects are generated to represent each specific instance
taking on its explicit states accordingly (see Fig. 1 for an
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example of a statechart). This resulted in a comprehen-
sive and reactive computational model.
The tumor and its microenvironment act together as
an organ, which defines the ‘world’ of the model. The
model begins with a single cancerous cell, which prolif-
erates to gradually form a primary tumor, consisting of
cancerous cells that originated from the initial one. Each
cell has its specific 3D position within this world and
takes on its own behavior, depending on its current state
and surroundings.
Controlled by the Statechart driving its behavior, the
tumor cell constantly senses its immediate surroundings,
and consumes available oxygen at a certain level. If it
cannot consume a sufficient amount of oxygen, it will
not be able to proliferate, will go into a state of hypoxia
and will secrete angiogenic factors (VEGF). The VEGF is
secreted in pulses, and continues to be secreted until the
cell is able to consume enough oxygen so as not to be in
a state of hypoxia. The VEGF diffuses from the specific
tumor cell and moves in a random manner. If the cell
continues to lack oxygen it enters a state of anoxia,
becoming necrotic and no longer active.
A number of blood vessels, made up of individual endo-
thelial cells, are initially located either around the border
of the defined world, or at random positions therein. The
endothelial cells are of roughly the same size as the tumor
cells, and similarly sense their environment constantly.
Once they bind to an amount of VEGF above a specified
threshold within a certain amount of time, they become ac-
tivated and begin the process of angiogenesis, where the
vessels elongate in a direction that follows the VEGF gradi-
ent. This occurs by proliferation of those endothelial cells
that have become activated and continues for as long as the
endothelial cell continues to bind enough VEGF for its con-
tinuation. If the endothelial cell encounters another endo-
thelial cell, it will join it and stop elongating. Activated
endothelial cells can also split and branch out of their main
vessel if they bind a high amount of VEGF in a short
amount of time. Due to the delta-notch inhibition between
adjacent cells, once an endothelial cell is activated, the
neighboring cells cannot become activated too [53, 54].
The endothelial cells secrete oxygen at a constant rate, and
like the VEGF molecule, the oxygen diffuses out of the cell
in a random manner and is eliminated when consumed.
In this way, the newly produced blood vessels make
their way to the tumor, in the process forming a unique
spatial organization, and as a result the tumor continues
to grow. Newly produced endothelial cells that do not
continue to receive a minimum amount of VEGF cannot
survive and eventually cause the death of the vessel of
which they are part.
Fibroblast cells [1], which are the main components of
the ECM, are initially placed randomly around the
tumor. During the model’s execution, those that are
Fig. 1 Statechart of a cell. An example of a statechart that was used in the model
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close to the tumor cells and have enough oxygen have a
greater chance of becoming activated into CAFs (cancer
associated fibroblasts) [55]. CAFs secrete VEGF in cor-
relation with their hypoxia state [56], which helps recruit
the blood vessels. They also secrete HGF (Hepatocyte
Growth Factor), which helps the tumor cells proliferate,
as well as degrade the ECM around them, which, in
turn, helps tumor cells move. CAFs themselves are mo-
tile and move towards the tumor [57, 58] by following
the gradient of FGF (Fibroblast Growth Factor) that is
secreted by the tumor cells. This type of movement can
casue entry of CAFs into the tumor [55].
The SimuLife animation tool
Whilst the Statechart model holds the information of
each of the individual objects, SimuLife makes it pos-
sible to visualize the information of all the objects to-
gether at once [50]. This helps greatly when developing
the model; to be able to see the dynamics of the whole
system, verify the behavior, fine-tune the model as a
consequence, and examine the effect of the parameters
on the system.
Results analysis
Many parameters were incorporated into in the model.
Since we do not use every biological aspect whilst mod-
eling, the parameter values do not represent exact meas-
urement values but only values that are logical relative
to each other. In addition, the values of the parameters
in the model are unit-less (for a list of parameters, see
Additional file 1). What guides us when adjusting par-
ameter values is the behavior of the element in the
model and that this matches the actual behavior of the
real biological element it represents.
In order to check the correctness of the whole model
and understand the behavior of the system, analysis was
performed on the data retrieved from the model, and it
was compared to existing biological data.
First, we wanted to verify that the behavior of the sys-
tem modeled is consistent with that of a real cancerous
tumor. This was done by looking at a number of points
of comparison:
1) The overall fundamental behavior of a solid tumor,
where the malignant cells proliferate into a primary
tumor until they lack sufficient oxygen and nutrients,
and then send out VEGF in order to recruit new
blood vessels, which arrives at the endothelial cells of
the original blood vessels [59, 60]. The VEGF
molecules will have an affect only after enough
molecules have arrived to initiate angiogenesis, a
process that can take up to a few days. The vessels, in
turn, grow towards the concentration gradient and
supply the tumor with oxygen/nutrients, enabling it to
continue growing. The vessels arrive at the tumor
within anything from a few days to a few weeks [61],
creating a new network [6, 10].
This behavior is found in the model, and when
visualized by using Simulife (Fig. 2) compares
favorably to images found in [62, 63].
In addition, a necrotic core is formed in the inner
part of the tumor where the cells do not receive
enough oxygen and undergo necrosis [64, 65]
(Figs. 3 and 4). This occurs as the tumor expands
and the inner cells are no longer exposed to oxygen.
The necrotic core occupies from a few percent of
the tumor up to the majority of its volume,
depending on the amount of available oxygen.
Fig. 2 SimuLife image of the tumor. A SimuLife image of the tumor surrounded by vessels and fibroblasts (green) as created by the Statecharts
model. Shown from two different angles
Bloch and Harel BMC Bioinformatics  (2016) 17:317 Page 4 of 15
Fig. 3 Slicing of the tumor in SimuLife; the necrotic core (dark blue) can be seen
Fig. 4 Distribution of cells. Distribution of the different cells as a function of the distance from the center of the tumor (x = 0) at time step 788.
Necrotic cells (light blue) occur at the center of the tumor. Vessel splits (red) occur more as they approach the tumor (blue)
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The blood vessels branch more as they approach the
tumor (the brush-border effect, [66–68]). This
occurs as endothelial cells that are closer to the
tumor sense more VEGF and are therefore activated
more easily to sprout and form new vessels (Fig. 4).
The diffusion behavior of the VEGF and oxygen
molecules can be verified by their distribution over
time. Molecules diffuse in space, forming a
symmetric, decreasing gradient [69]. In the model,
oxygen is initially present everywhere but is
gradually consumed by the tumor and in parallel is
secreted by vessels. VEGF is secreted by the tumor
(and partly by fibroblasts) and spreads out while
being consumed by the endothelial cells (Fig. 5). The
molecules diffuse by moving in a random fashion
from their point of secretion, gradually occupying
available space.
It is important to note that the above anticipated
behaviors of the system (necrotic core, increased
branching near the tumor, and distribution of
diffused molecules) emerged bottom-up from the
behavior of the individual components and rules of
the system, and not by inserting such behavior into
the model explicitly.
2) The dynamic behavior of the various cells and
molecules as observed from running and
analyzing the model, agrees with that found in
literature. In (Fig. 6) we see that the emergent
behavior of the system results in an initial linear
growth of tumor cells, a halt in the growth
(due to lack of oxygen), then growth of
endothelial cells, and consequently an exponential
growth in the number of tumor cells. This can be
compared to results found in [70–73], where the
growth of tumor cells and blood vessels exhibit a
similar pattern.
3) Further verification included checking that “normal”
cases occur in the model. This included testing the
system under the following sets of circumstances:
a) No angiogenesis, which resulted in a primary
tumor that stopped growing at some point due to
low oxygen/nutrient supply, and then started to
die off [74–77] (Fig. 7).
b) Non-cancerous and non-proliferating cells, which
are able to live on normally without angiogenesis
(Fig. 8).
c) Blood vessels placed far from the tumor cells
(at ~300 μm instead of ~200 μm, where each
position in the model corresponds to 5 μm),
which results in no angiogenesis, and hence not
enough oxygen, leading to a non-active tumor
[77–79] (Fig. 9).
The values of the parameters used in the model can be
changed easily. Playing with the values of these parame-
ters, as well as with other parts of the model, helped to
Fig. 5 Distribution of molecules. Distribution of oxygen (blue) and VEGF molecules (green) as a function of the distance from the center of the
tumor (x = 0) at different time steps throughout the simulation (left column followed by right column, from top to bottom). Oxygen is initially
present everywhere but is gradually consumed by the tumor and in parallel secreted by vessels. VEGF is secreted by the tumor and spreads out
while being consumed by the endothelial cells. The VEGF in the first two graphs is due to secretion by fibroblasts and not by the tumor
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gain a better understanding of their effect on the behavior
of the system.
High vs. low oxygen secretion
Playing with the parameter OxygenSecretionAmount,
which represents the number of oxygen units secreted
every pulse in the simulation, reveals that very low oxy-
gen secretion slows down the growth of the tumor until
it is almost completely eliminated. However, as long as
some cells are still active, they manage to recover from
the situation and end up growing into a large tumor, as
large as when OxygenSecretionAmount is high, but later
in time (Fig. 10). Therefore, above a certain threshold of
minimum oxygen secretion, the tumor and vessels will
eventually develop to their full competence. Below this
threshold, a tumor will not develop in the model.
Although in reality tumor cells deprived of oxygen can
produce energy by fermenting sugars (Warburg effect,
[80]), and become even more aggressive, the oxygen in
our model represents both actual oxygen and nutrients.
High vs. low VEGF secretion
VEGF secretion by the tumor cells is what recruits the
vessels towards the tumor in order to supply it with oxy-
gen/nutrients. Playing with the parameter VEGFSecretio-
nAmount, the amount of VEGF units secreted by the
tumor cells at every pulse in the simulation, reveals that,
here too, very low VEGF secretion results in tumor and
vessels similar to those resulting from high VEGF, al-
though it takes longer, as vessels take more time to be-
come activated by the VEGF (Fig. 11). This indicates
that the tumor system is insensitive to the amount of
Fig. 6 Tumor cell and endothelial cell dynamics in the simulation. The behavior of the tumor cells and vessels in the model can be compared to
biological results
Fig. 7 No angiogenesis. Tumor does not develop. Left: tumor cell and endothelial cell dynamics. Right: image of the same run in SimuLife
(blue cells are necrotic)
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VEGF, as long as there is some VEGF secreted by the
tumor cells. Since there are many secreting cells in a
tumor, the VEGF will eventually reach and activate the
nearby vessels.
High vs. low angiogenic switch threshold
In order for the endothelial cell to be activated for
angiogenesis, it needs to meet a minimum amount of
VEGF in a certain amount of time [76]. Playing with the
parameter AngiogenicSwitchThreshold, which represents
the minimum amount of VEGF needed to initiate angio-
genesis, reveals once again that there is a threshold for
this parameter; any value above it means that it will take
the vessels too long to become activated, and they won’t
arrive at the tumor in time before it dies. Below this
value the tumor survives and arrives at the same end
point, but the time it takes it takes the tumor to develop
depends on the value: the lower the threshold the faster
the occurrence of angiogenesis (Fig. 12).
High vs. low hypoxia level
Hypoxia (insufficient oxygen supply) in the model oc-
curs after a cell has not consumed a sufficient amount
of oxygen for the duration of HypoxiaLevel time steps.
At this point the cell continues to live but cannot prolif-
erate. If it is a tumor cell, it also begins to secrete VEGF
in order to recruit blood vessels. At high levels of
HypoxiaLevel the tumor grows more before needing the
help of angiogenesis. When the tumor cells do eventu-
ally secrete VEGF molecules, there are many cells that
do so, hence angiogenesis occurs fast and the tumor
continues to grow. When HypoxiaLevel is too low, the
tumor cells lose their ability to proliferate very fast and
so the VEGF they secrete is not enough to recruit the
vessels in time before the tumor dies. Once again, values
Fig. 8 No angiogenesis. Non-cancerous and non-proliferating cells live on. Left: tumor cell and endothelial cell dynamics. Right: image of the
same run in SimuLife
Fig. 9 Initial blood vessels are too far away. Tumor does not develop. Left: tumor cell and endothelial cell dynamics. Right: image of the same
run in SimuLife (blue cells are necrotic)
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higher than the minimum threshold will eventually
result in a developed tumor, but at different time dura-
tions–the lower the value the more time it will take.
High vs. low anoxia level
Anoxia (total depletion in the level of oxygen) refers to
when the cell is completely out of oxygen and cannot
continue to live. At this stage it will become necrotic (an
un-programmed, unnaturally occurring cell death–as
opposed to apoptosis). This occurs at a later stage than
hypoxia, after the cell has had insufficient oxygen for a
duration of AnoxiaLevel time steps. When this level is
very high no necrotic core occurs, since although all
cells may not be proliferating, they live on. At very low
levels the entire tumor dies out very fast. Values in
between form necrotic cores of different sizes, depend-
ing on the value of the parameter, but since the outer
cells continue to receive oxygen, the tumor as a whole
continues to develop.
A list of the VEGF and Oxygen parameters that were
used for analysis, as well as the range of values thereof
that ensures tumor recovery and development can be
found in Additional file 1.
In each of the conditions described above, if the tumor
recovered from just a few surviving cells, those cells are
considered the stronger, more aggressive ones (survival
of the fittest [81]).
This analysis indicates that the tumor is in fact a very
robust system. On the one hand, each of the key parame-
ters has a threshold, which, if crossed, the tumor does not
develop. However, at the same time, any value within the
range allows the tumor to eventually become fully devel-
oped, even if it takes longer and the tumor has to overcome
tough conditions. (A short clip showing these results in
SimuLife can be found in Additional file 2.) The issue of
robustness of the tumor was raised in the past [82], where
it was suggested that this fact calls for new therapeutics.
Moreover, what we saw in all runs of the model, espe-
cially in those where the tumor recovered from tough
conditions, was the phase transition in the tumor cell
dynamics. At first, the tumor grows linearly, consuming
oxygen from its surroundings. The growth then slows
Fig. 10 High vs. low oxygen secretion simulations. Top: graph of tumor cells showing that at a low oxygen level the tumor cells drop to almost
zero at ~800ts but recover and reach 16,000 cells at ~1100ts, whereas at a high oxygen level they do not demonstrate a drop and reach 16,000
cells shortly after ~800ts. Bottom: images of these runs in SimuLife (left for low oxygen, right for high oxygen), presenting amounts on their left
tab. Both images are presented at approximately the same time step – at low oxygen only few active tumor cells are present, at high oxygen the
tumor consists of many cells where almost all are active
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Fig. 11 High vs. low VEGF secretion simulations. Top: graph of endothelial cells showing that at low VEGF the endothelial cells are activated at ~600ts
and reach ~5000 cells at ~900ts, much later than at high VEGF secretion, which begins at ~400ts and reaches ~5000 cells at ~700ts. Bottom: images of
these runs in SimuLife (left for low VEGF, right for high VEGF), presenting amounts on their left tab. Both images are presented at approximately the
same time step–at low VEGF angiogenesis has only begun, whereas at high VEGF there are many activated and branched vessels
Fig. 12 High vs. low angiogenic switch threshold simulations. Graph of tumor cells and endothelial cells at low angiogenic switch threshold
(light colors), and high angiogenic switch thresholds (dark colors). They reach approximately the same levels, but at a time shift of ~200ts. Also,
at high angiogenic thresholds we see that the tumor almost dies at ~900ts, but then recovers
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down, and sometimes even decreases, due to low oxygen.
When enough blood vessels finally arrive at the tumor
and feed it with a large quantity of oxygen, the tumor cells
start growing exponentially (Fig. 13). At this point, the
amount of cells increases, requiring more oxygen, and the
cells therefore secrete more VEGF, and in turn receive
more oxygen. In this way, the tumor and its surroundings
maintain themselves. This is a critical turning point for
the tumor, since if it does not manage to pass this point, it
will simply die. This finding supports the need to treat
tumors as early as possible [83, 84].
Conclusions
Cancer affects many people. It is researched in numerous
labs around the world, in order to understand its function
and behavior better and to develop possible treatments.
Cancer is a multi-scale and complex system, where the
tumor and its microenvironment work together in a way
similar to an organ. Applying advanced computational
techniques to this system is complementary to classical
ongoing research. It enables the integration of a variety of
data and helps one see the big picture.
In our research we used the language of Statecharts
with the Rhapsody tool in order to create a comprehen-
sive 3D model of a cancerous solid tumor, together with
its microenvironment. The model was constructed in a
bottom up method, where the behavior of each kind of
participating component was built individually, and the
system’s overall dynamic behavior emerged from those
of the elements thereof.
In order to better understand biological models there is a
need for detailed and realistic visualization. For this pur-
pose the SimuLife tool was developed, where an animation
is dynamically constructed at real time, producing an inter-
active visualization of the system’s runs. It shows the tumor
cells at their precise 3D locations, together with the blood
vessels that consist of the individual endothelial cells. The
blood vessels elongate towards the tumor by following the
VEGF gradient, and in turn secrete oxygen. Cell prolifera-
tion or death (in the case of tumor cells this is necrosis),
and molecule movement can be observed too. SimuLife
allows one to easily play with the animation, send com-
mands back to the model during runtime and observe the
immediate resulting output. A more detailed description of
SimuLife and its abilities can be found in [50].
Using the SimuLife tool, we were able to see that the
model matched the behavior of a solid tumor in a number
of ways: It developed an inner necrotic core, the branching
of the blood vessels occurred more often as they
approached the tumor, the VEGF molecules that were
secreted from the tumor cells diffused and were distrib-
uted throughout space until reaching the blood vessels,
the oxygen secreted from the endothelial cells was also
diffused and finally reached and was consumed by the
tumor cells. In addition, the dynamic behavior of the vari-
ous cells showed patterns similar to those found in real tu-
mors. Further verification was carried out to test known
cases within the model. This included verifying that the
tumor cannot continue to grow without angiogenesis, that
a non-cancerous cell can continue to live on without
angiogenesis, and that when placing blood vessels far from
the tumor angiogenesis does not take place.
From analyzing the components of the model by look-
ing at their qualitative and quantitative dynamics, play-
ing with the different parameters, and inspecting and
analyzing the resulting animations, we conclude that the
Fig. 13 Tumor cell dynamics. Just before 800ts there is a turning point for the tumor and a phase transition
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tumor has a turning point, which depends on thresholds
of the key parameters that effect amounts of VEGF and
oxygen. At this point, the tumor either dies, or recovers
and continues to develop to become a full, actively
growing tumor. Thus, the tumor’s growth may be halted
or declined while it waits for the blood vessels to deliver
oxygen. If the oxygen arrives in time, while there are still
surviving tumor cells, a phase transition will occur in
the tumor’s growth, and from a linear growth rate it will
suddenly start growing exponentially. The VEGF and
oxygen parameters (amount secreted, consumption, acti-
vation threshold….) are what affect the fate of the tumor
in this case. If the thresholds are met and the fate of the
tumor is to continue, the values of these parameters do
not make a big difference. A tumor that survives will de-
velop similarly within the range of allowed values, the
main difference being in the time it takes.
It is known that a tumor cannot continue to grow
above a certain size (~1 mm3) without angiogenesis [6,
85, 86]. The angiogenic switch point is when the blood
vessels have bound enough VEGF to begin angiogenesis
[87] and deliver oxygen and nutrients to the tumor. Evi-
dence has shown that tumor growth is slow and linear
before vascularization and rapid and nearly exponential
after vascularization [88, 89]. Therefore, the essential
need of VEGF to recruit blood vessels, and oxygen and
nutrients for the tumor to continue growing is con-
firmed. Here, we suggest that not only is there an angio-
genic switch turning point that causes the tumor to
enter exponential growth, but there is also a recovery
turning point. This means that: 1) if the tumor cells
secrete VEGF in any amount, the blood vessels will
eventually arrive at the tumor, and 2) if at least some
active tumor cells are alive when the blood vessels arrive
at the tumor, and if they deliver a sufficient amount of
oxygen for those cells to continue their activity, the
tumor will eventually become fully developed, even if it
takes longer. This also suggests that the tumor, together
with its microenvironment, is a robust system, reaching
its maximum outcome if the minimum conditions are
met, regardless of the actual amounts. It therefore seems
like the tumor does not economize resources, and sends
well over the needed angiogenic factors.
These conclusions may provide further evidence as to
why inhibiting VEGF, or reducing the supply of oxygen
and nutrients to the tumor, does not always result in its
complete elimination. This is especially relevant to anti-
cancer treatments other than chemotherapy, such as
VEGF inhibitors [90], or destruction of the tumor’s
surrounding blood vessels and hence elimination of its
oxygen supply, such as is done in photodynamic therapy
[91–95]. These treatments, according to the model’s
results, can extend the time it takes the tumor to
become fully developed.
Methods
The Statecharts modeling language
Our model was designed using the visual language of
Statecharts [96, 97], which was invented as a system
engineering tool to aid in the design of complex
reactive systems [96, 98], where the components react
to each other and to the environment. The language
makes possible the dynamic and visual specification
and execution of reactive behavior via the use of in-
tuitive, yet completely formal and fully executable,
diagrams. Statecharts describe discrete behavior using
states, and events that cause transitions between the
states. Orthogonal/concurrent states may also be spe-
cified, such that the system or parts thereof may be
in several different states simultaneously, in accord-
ance with the different stages of the simulation. In
addition, the language is hierarchical, so that states
may contain substates, which enable description at
multiple levels, as well as level-rich transitions. The
object-oriented version of the Statecharts language
[97] is based on an intra-object philosophy; i.e., on
supplying the full description of the internal behavior
of each of the participating objects.
Statecharts and their execution are supported by sev-
eral appropriate tools, such as Rhapsody, which was co-
designed by the second-listed author, and is available
from IBM (www.ibm.com/software/awdtools/rhapsody/).
The language has become very useful in modeling a
variety of biological systems (see past [44–47, 99]),
since these are in fact complex reactive systems; they
interact with, and respond to, both the environment
and other parts within the system [48, 98]. We have
used Statecharts to specify the behavior of the indi-
vidual entities that take part in the cancer process, in
order to capture the dynamic behavior and morphology of
the system.
SimuLife, a 3D animation tool
SimuLife is an interactive animation tool we have built
for visualizing models of cellular biology [50]. It can
receive inputs from the model, as well as send informa-
tion to the model (both sent as XML files) and draws
the appropriate animated graphics based on the
changes. This makes it possible to see the ongoing
events of the entire model on the screen in real time
[51, 52]. SimuLife is based on WebGL (Web Graphics
Library), a JavaScript API (THREE.js framework in our
case) for rendering interactive 3D graphics within any
compatible web browser without the use of plug-ins.
The client side is Chrome and the communication with
external engines is done via sockets. The realistic im-
ages used within SimuLife (e.g., of a cell) are in the
COLLADA format.
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Additional file 1. Further details of the model. Details regarding the
specification of the model, together with a list of the parameters used in
the model and their default values, and the range of values for VEGF and
oxygen parameters that ensure tumor recovery. (PDF 244 kb)
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